Decision Diagnostics (OTCMKTS:DECN) vs. Privia Health Group (NASDAQ:PRVA) Critical Contrast

Privia Health Group (NASDAQ:PRVA) and Decision Diagnostics (OTCMKTS:DECN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Privia Health Group has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Decision Diagnostics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Earnings & Valuation

This table compares Privia Health Group and Decision Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$1.74 billion	1.67	$14.39 million	$0.13	181.85
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A

Privia Health Group has higher revenue and earnings than Decision Diagnostics.

Insider and Institutional Ownership

94.5% of Privia Health Group shares are owned by institutional investors. 10.7% of Privia Health Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Privia Health Group and Decision Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0	3	12	0	2.80
Decision Diagnostics	0	0	0	0	0.00

Privia Health Group currently has a consensus price target of $30.42, suggesting a potential upside of 28.67%. Given Privia Health Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe Privia Health Group is more favorable than Decision Diagnostics.

Profitability

This table compares Privia Health Group and Decision Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Privia Health Group	0.89%	2.52%	1.47%
Decision Diagnostics	N/A	N/A	N/A

Summary

Privia Health Group beats Decision Diagnostics on 10 of the 10 factors compared between the two stocks.

About Privia Health Group

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.